To prescribe VUMERITY® (diroximel fumarate), please follow these steps:

1 After discussing VUMERITY with your patient, have your patient read the Patient Consent Information and, if interested, respond accordingly on the accompanying Start Form.

Biogen takes your patient's confidentiality very seriously. While patients are not required to sign the Start Form in order to receive VUMERITY, signing these lines will expedite their enrollment in **Biogen Support Services**, such as the **Biogen Copay Program** (call 1-800-456-2255 for eligibility guidelines). In addition, with these signatures Biogen will have access to your patient's prescription status should you or your patient need assistance.

Complete the rest of the Start Form.
Copy both sides of the patient's medical insurance card and pharmacy benefit card, if available. In some cases, the medical and pharmacy cards may be the same.

Give your patient the Instructions for Patients and Patient Consent Information guides. Then, fax the Start Form to 1-855-474-3067. Prescriptions are only valid when received via fax.

Your patient will be contacted by a pharmacy in the VUMERITY Pharmacy Network to arrange for delivery of the prescription.

Please be sure to fill out all of the sections of the Start Form. Incomplete areas may delay the start of treatment.

Instructions for Patients

How do I get started?

- 1 Read the Patient Consent Information and respond accordingly in Sections A, B, C, and D of the Start Form. This will enable you to enroll in **Biogen Support Services**, such as the **Biogen Copay Program** (call 1-800-456-2255 for eligibility guidelines).
- **Be sure to include your email address in the space provided.** By giving us your email address, you can stay up to date on the latest news about VUMERITY.
- 3 Your healthcare provider fills out the rest of the Start Form. You're done. Your healthcare provider will fax us the Start Form.

What happens next?

- You can expect to receive several important phone calls. These calls will come from a **Biogen Support Coordinator** and a pharmacy certified to dispense VUMERITY.
 - You'll see 919-993-7000, a 1-800 number, or "unknown" on your caller ID. Please be sure to answer when you see these calls. They are intended to help you in getting started on VUMERITY as smoothly and quickly as possible.
- Your prescription can be shipped directly to your home.

If you have any questions or want to learn more about VUMERITY, please call 1-800-456-2255 or visit <u>VUMERITY.com</u>.





Please read the following. If you agree, respond accordingly on page 4.

I. Authorization to Share Health Information

I understand that I have certain rights related to the collection, use, and disclosure of my medical and health information. This information is called "protected health information" (PHI) and includes demographic information (such as sex, race, date of birth, etc.), the results of physical examinations, clinical tests, blood tests, X-rays, and other diagnostic medical procedures that may be included in my medical records. Biogen will not use my PHI without my consent.

By signing this Authorization, I authorize my healthcare provider, my health insurance company, and my pharmacy providers ("Healthcare Entities") to disclose to Biogen, and companies working with Biogen (collectively, "Biogen"), health information relating to my medical condition, treatment, and insurance coverage for Biogen to (i) provide me with support services (and related information and materials) related to any of Biogen's products, including but not limited to, online support, financial assistance services, compliance and persistency and other therapy support services, and (ii) conduct data analysis, market research and other necessary internal business activities, and (iii) provide me with information about Biogen's products, services, and programs for educational or other purposes. I understand that once I sign this Authorization, and my medical and health information is disclosed to Biogen by the Healthcare Entities, the Health Insurance Portability and Accountability Act (HIPAA) will no longer protect my information because Biogen is not covered by HIPAA. However, Biogen agrees to protect my health information by using and disclosing it only for purposes authorized in this Authorization or as required by law or regulations. I understand that my pharmacy provider may receive remuneration from Biogen in exchange for the health information and/or for any therapy support services provided to me.

I understand that I may refuse to sign this Authorization. I further understand that my treatment (including with a Biogen product), payment for treatment, insurance enrollment or eligibility for insurance benefits are not conditioned upon my agreement to sign this Authorization; but if I do not sign it or later cancel it, I will not be able to receive Biogen's therapy support services.

I may cancel this Authorization at any time by mailing a letter to: Biogen, ATTN: Patient Services, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC, 27709 or emailing privacy@biogen.com. Canceling this Authorization will end my consent to further disclosure of my health information to Biogen by my Healthcare Entities after they are notified of my cancellation but will not affect previous disclosures by them pursuant to this Authorization. Canceling this authorization will not affect my ability to receive treatment, payment for treatment, or my eligibility for health insurance.

This Authorization expires ten (10) years, or such shorter timeframe required by applicable law, from the day I sign it as indicated by the date next to my signature unless otherwise canceled earlier as set forth above.

Please sign in the space in Section $oldsymbol{\mathsf{A}}$ on page 4 to authorize your consent.

II. Patient Services Authorization

By signing this Authorization, I authorize Biogen, and companies working with Biogen, to provide me with support services related to any of Biogen's products, including but not limited to: online support, financial assistance services, compliance and persistency and other therapy support services, as well as any information or materials related to such services. I understand and agree that personnel, including but not limited to nurses, providing such support services on behalf of Biogen are not employed by my healthcare professional. I authorize Biogen, and companies working with Biogen, to contact me to provide such services and information by mail, email, fax, telephone call, text message (including calls and text messages made with an automatic telephone dialing system or a prerecorded voice), chat, push notifications and other forms of electronic messaging.

I also authorize Biogen, and companies working with Biogen, to use and disclose my medical and health information in connection with providing the services, including but not limited to, disclosing my information to vendors, processors, and service providers for business purposes associated with providing the services, sharing such information with my healthcare provider, insurance provider, or pharmacy, or disclosing my information where required by applicable laws or regulations. I also authorize the disclosure of my health information to specific individuals that I have designated.

Please sign in the space in Section B on page 4 to authorize your consent.

Continued on following page.



Please read the following. If you agree, respond accordingly on page 4.

III. Marketing Authorization

By signing this Authorization, I authorize Biogen, and companies working with Biogen, to contact me by mobile or online digital media, mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen's products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by Biogen for marketing, including targeted online marketing, as well as to develop new products, services, and programs. I understand that Biogen will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Biogen. I understand that I may revoke this authorization and choose not to receive information from Biogen by using the link provided in emails I receive from Biogen, sending an email with the subject "Unsubscribe" to privacy@biogen.com, or mailing a letter to Biogen, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC 27709. For more information visit biogen.com/privacy.

Please sign in the space in Section (on page 4 to authorize your consent.

Residents of certain US States (including but not limited to California) may have additional rights regarding the collection, use, maintenance, disclosure, and deletion of your personal information. To understand or exercise those rights California residents please visit https://www.biogen.com/privacy-center.html. For more information, visit https://www.biogen.com/privacy-center.html.

I understand that I have the right to receive a copy of the terms and conditions of my agreement with Biogen, and that I may request that copy at the time of signing or at a later date by contacting Biogen at: Biogen, ATTN: Patient Services, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC, 27709 or emailing privacy@biogen.com.

IV. Government Payer Attestation

Patients with federally funded insurance or a commercial insurer that restricts or prohibits participation in Manufacturer Assistance Program(s), are NOT eligible for certain Biogen programs (such as VUMERITY QuickStart or Biogen Copay Assistance). Patients insured through Medicaid, Medicare, VA, DoD, TRICARE®*, and other governmental insurance are NOT eligible for these programs.

I attest that I either (i) currently do not have federally-funded health insurance, or (ii) will not use my federally funded health insurance to cover any portion of the costs of my Biogen medication while I am enrolled in the certain Biogen programs, and (iii) I agree to notify Biogen immediately if I obtain a federally-funded insurance plan during my enrollment in certain Biogen programs and/or choose to use it to cover any portion of the costs of my Biogen medication so that I may be removed from the program.

*TRICARE® is a registered trademark of the Department of Defense, DHA. All rights reserved.

Please check the applicable box in Section oxdot on page 4 to attest whether or not you have a government payer.



| . Authorization to Share H have read and understand the Auth | | | gree to the terms. | Patient Information | | Female | |
|--|--|--|--|--|---|--|--|
| Signature of patient or patient re f signed by patient representative, p | - | Date ty to act on behalf of | the patient: | Date of birth | | Patient's preferred la | nguage |
| I. Patient Services Authoriza have read and understand the Pat | | ation and agree to th | no torms | First name | | MI Last nam | е |
| nave read and understand the Pat | ient services Authorizo | ation and agree to tr | ie terms. | Address | | 100 | 1 |
| Signature of patient or patient ren n addition, I authorize the disclosur ndividual(s) (optional): | - | Date mation to the following | ng designated | City | | State | Zip |
| | | | | Email address | | | |
| Care partner (print name) | | Relatio | nship | | | Preferred nu OK to leave vo | mber oicemail and/or text messa |
| Care partner email | | Phone | | Home phone (patient) | | Preferred nu | mher |
| II. Marketing Authorizatio | | | | Cell phone (patient) | | | icemail and/or text messa |
| have read and understand the Mark | keting Authorization ar | nd agree to the terms | 5. | _ | out mossage and | l/or omail with care parts | nor |
| Signature of patient or patient re | presentative | Date | | OK to leave voicemail, to Best time to reach me: | • | | |
| V. Government Payer Atte | station | | | | | / Lveriii | 6 |
| Please check the applicable box to | attest whether or r | | | ★ Pharmacy Benefit Ir | | | |
| I attest that I <u>do</u> have a federally costs associated with my Biogen | | ince and intend to us | e it to cover the | Attach copies of both s | | • | * * |
| I attest to all of the statements in a federally funded health insurance | | ious page and confirm | that I do not have | Check if no coverage | ☐ Check if pa | atient has secondary ir | surance |
| any portion of the costs of my Bio | e or will not use my fe gen medication while ! | ederally funded health I am enrolled in certaiı | insurance to cover n Biogen programs. | | -141 | | |
| Medical Benefit Information | n | | | Patient's preferred speci | laity pharmacy | | |
| Please provide copies of front and | back of all medical | and prescription in | surance cards. | PBM name | | PBM phone nur | nber |
| | | | | | | · | |
| Primary insurance | Policy | # | | RxBin F | RxPCN | Rx group # | Rx ID # |
| Group # | Insura | nce company phone | <u> </u> | | | | |
| droup # | Ilisula | rice company priorie | - | Policyholder first name | | Policyholder las | name |
| | Policyl | nolder last name | | | | | |
| Policyholder first name | , | | | | | | |
| Policyholder first name Samples have been received | THE FOLLOWIN | | N SHOULD BE | FILLED OUT BY YOUR H Statement of Medi | | | |
| Samples have been received Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID | THE FOLLOWIN by patient (231 mg) x7 days | # of bo | | | cal Necessity | | |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills | THE FOLLOWIN | # of bo | | ★ Statement of Medi ICD-10: G35 Primary diagnosis | cal Necessity | y | ☐ No prior disease |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID | THE FOLLOWIN by patient (231 mg) x7 days | # of bo | | ★ Statement of Medi ICD-10: G35 Primary diagnosis | cal Necessity | y | |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: | THE FOLLOWIN by patient (231 mg) x7 days x23 days | #14 capsules #92 capsules | ottles provided | ★ Statement of Medi ICD-10: G35 Primary diagnosis | cal Necessity | y | |
| □ Samples have been received □ Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days | #14 capsules #92 capsules #360 capsules #120 capsules | ottles provided 3 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera | cal Necessity | y | □ No prior disease modifying therap |
| □ Samples have been received □ Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 580 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days | #14 capsules #92 capsules #360 capsules #120 capsules | ottles provided 3 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera | cal Necessity | y | ☐ modifying therap |
| □ Samples have been received □ Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction | #14 capsules #92 capsules #360 capsules #120 capsules | ottles provided 3 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: | pies: | y | ─ modifying therap☐ No Known Drug |
| Samples have been received Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for co | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction | #14 capsules #92 capsules #360 capsules #120 capsules asi. | 3 refills 11 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa | pies: | y | ─ modifying therap☐ No Known Drug |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for co □ Yes, I authorize Biogen to prov (one Titration Rx and ongoing coverage is secured. I authorize pharmacy to dispense VUMER | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days rovider Instruction pride up to 4 months of Maintenance Rx, as it es Biogen to forward ITY directly to the ab | #14 capsules #360 capsules #120 capsules atients only*) of VUMERITY to my pneeded) until the paths prescription to ove-named patient. | 3 refills 11 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa | pies: | y | ─ modifying therap☐ No Known Drug |
| □ Samples have been received in Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for come Titration Rx and ongoing coverage is secured. I authorize pharmacy to dispense VUMER are needed for (A) and (B) about *Patients insured through Mexical Patients in | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction mercially insured p vide up to 4 months of Maintenance Rx, as re directly to the ab ve to expedite enroll dicaid. Medicare VA | #14 capsules #360 capsules #360 capsules #120 capsules batients only*) of VUMERITY to my pneeded) until the pathis prescription to ove-named patient. ment. DOD. TRICARE®, an | 3 refills 11 refills batient at no cost tient's prescription the designated Patient signatures and other | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa | pies: | Dates: | ─ modifying therap☐ No Known Drug |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for coverage is secured. I authorize pharmacy to dispense VUMER are needed for (A) and (B) above | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction mercially insured p vide up to 4 months of Maintenance Rx, as re directly to the ab ve to expedite enroll dicaid. Medicare VA | #14 capsules #360 capsules #360 capsules #120 capsules batients only*) of VUMERITY to my pneeded) until the pathis prescription to ove-named patient. ment. DOD. TRICARE®, an | 3 refills 11 refills batient at no cost tient's prescription the designated Patient signatures and other | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address | pies: | Dates: | ☐ Mo Known Drug ☐ Allergies (NKDA) |
| Samples have been received by Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for compartment of the coverage is secured. I authorize pharmacy to dispense VUMER are needed for (A) and (B) abo *Patients insured through Met governmental insurance are trademark of the Department | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction mercially insured p vide up to 4 months of Maintenance Rx, as re directly to the ab ve to expedite enroll dicaid. Medicare VA | #14 capsules #360 capsules #360 capsules #120 capsules batients only*) of VUMERITY to my pneeded) until the pathis prescription to ove-named patient. ment. DOD. TRICARE®, an | 3 refills 11 refills batient at no cost tient's prescription the designated Patient signatures and other | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name | pies: | Dates: | ─ modifying therap☐ No Known Drug |
| □ Samples have been received in Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for come Titration Rx and ongoing coverage is secured. I authorize pharmacy to dispense VUMER are needed for (A) and (B) about *Patients insured through Mexical Patients in | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction mercially insured p vide up to 4 months of Maintenance Rx, as re directly to the ab ve to expedite enroll dicaid. Medicare VA | #14 capsules #360 capsules #360 capsules #120 capsules batients only*) of VUMERITY to my pneeded) until the pathis prescription to ove-named patient. ment. DOD. TRICARE®, an | 3 refills 11 refills batient at no cost tient's prescription the designated Patient signatures and other | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address City | pies: | Dates: Last name State | ☐ Mo Known Drug ☐ Allergies (NKDA) |
| Samples have been received in Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for company of the provious provious pharmacy to dispense VUMER are needed for (A) and (B) about pharmacy to dispense VUMER are needed for (B) and (B) about pharmacy to dispense VUMER are needed for (B) and (B) about pharmacy to dispense VUMER are needed for (B) and (B) about pharmacy to dispense VUMER are needed for (B) and (B) about pharmacy to dispense VUMER are needed for (B) and (B) about pharmacy to dispense VUMER are needed for (B) and (B) about pharmacy pharmacy pharmacy pharmacy pharmacy pharmac | THE FOLLOWIN by patient (231 mg) X7 days x23 days X90 days x30 days Provider Instruction Ommercially insured provide up to 4 months of Maintenance Rx, as ree Biogen to forward ITY directly to the above to expedite enroll dicaid, Medicare, VA NOT eligible for this t of Defense, DHA. And X7 days | #14 capsules #360 capsules #360 capsules #120 capsules ns. patients only*) of VUMERITY to my pneeded) until the paths prescription to ove-named patient. ment. ment. ment. ment. TRICARE*, an program. TRICARE*, an program. TRICARE*, all rights reserved. | 3 refills 11 refills batient at no cost tient's prescription the designated Patient signatures and other | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address | pies: | Dates: | ☐ Mo Known Drug ☐ Allergies (NKDA) |
| Samples have been received Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for company of the company of | THE FOLLOWIN by patient (231 mg) X7 days X23 days X90 days X30 days Provider Instruction Ommercially insured provide up to 4 months of Maintenance Rx, as realized in the above to expedite enroll dicaid, Medicare, VA NOT eligible for this t of Defense, DHA. A | #14 capsules #360 capsules #360 capsules #120 capsules stationary #360 to capsules #120 capsules #120 capsules #120 capsules #120 repsules #12 | 3 refills 11 refills batient at no cost tient's prescription the designated Patient signatures and other | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address City Phone | pies: | Dates: Last name State Fax | ☐ Mo Known Drug ☐ Allergies (NKDA) |
| Samples have been received by Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for compartment of the Department of the Dep | THE FOLLOWIN by patient (231 mg) X7 days x23 days X90 days x30 days Provider Instruction Ommercially insured provide up to 4 months of Maintenance Rx, as ree Biogen to forward ITY directly to the above to expedite enroll dicaid, Medicare, VA NOT eligible for this t of Defense, DHA. And X7 days | #14 capsules #360 capsules #360 capsules #120 capsules ns. patients only*) of VUMERITY to my pneeded) until the paths prescription to ove-named patient. ment. ment. ment. ment. TRICARE*, an program. TRICARE*, an program. TRICARE*, all rights reserved. | 3 refills 11 refills batient at no cost tient's prescription the designated Patient signatures and other | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address City | pies: | Dates: Last name State | ☐ Mo Known Drug ☐ Allergies (NKDA) |
| Samples have been received Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for company of the company of | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction Demonstrated provide up to 4 months of Maintenance Rx, as it are Biogen to forward IT directly to the above to expedite enroll dicaid, Medicare, VA NOT eligible for this it of Defense, DHA. And x7 days x7 days | #14 capsules #360 capsules #360 capsules #120 capsules ns. patients only*) of VUMERITY to my peeded) until the paths prescription to ove-named patient. ment. p. DoD, TRICARE*, an program. TRICARE* all rights reserved. | 3 refills 11 refills 22 refills 23 refills 24 refills 25 refills 26 refills 27 refills 28 refills 28 refills 29 refills 20 refills 20 refills 20 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 27 refills 27 refills 28 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 26 refills 26 refills 26 refills 26 refills 27 refills 27 refills 27 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 2 | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address City Phone | pies: | Dates: Last name State Fax | modifying therapy No Known Drug Allergies (NKDA) |
| Samples have been received by Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for compartment of the Department of the Dep | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction Demonstrated provide up to 4 months of Maintenance Rx, as it are Biogen to forward IT directly to the above to expedite enroll dicaid, Medicare, VA NOT eligible for this it of Defense, DHA. And x7 days x7 days | #14 capsules #360 capsules #360 capsules #120 capsules ns. patients only*) of VUMERITY to my peeded) until the paths prescription to ove-named patient. ment. p. DoD, TRICARE*, an program. TRICARE* all rights reserved. | 3 refills 11 refills 22 refills 23 refills 24 refills 25 refills 26 refills 27 refills 28 refills 28 refills 29 refills 20 refills 20 refills 20 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 27 refills 27 refills 28 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 26 refills 26 refills 26 refills 26 refills 27 refills 27 refills 27 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 2 | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address City Phone Email | pies: | Dates: Last name State Fax Tax ID # | modifying therapy No Known Drug Allergies (NKDA) |
| Samples have been received by Prescription for VUMERITY Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for compartment of the Department of the Dep | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction Demonstrated provide up to 4 months of Maintenance Rx, as it are Biogen to forward IT directly to the above to expedite enroll dicaid, Medicare, VA NOT eligible for this it of Defense, DHA. And x7 days x7 days | #14 capsules #360 capsules #360 capsules #120 capsules ns. patients only*) of VUMERITY to my peeded) until the paths prescription to ove-named patient. ment. p. DoD, TRICARE*, an program. TRICARE* all rights reserved. | 3 refills 11 refills 22 refills 23 refills 24 refills 25 refills 26 refills 27 refills 28 refills 28 refills 29 refills 20 refills 20 refills 20 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 27 refills 27 refills 28 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 26 refills 26 refills 26 refills 26 refills 27 refills 27 refills 27 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 2 | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name Address City Phone Email | pies: | Dates: Last name State Fax Tax ID # | modifying therapy No Known Drug Allergies (NKDA) |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for come Titration Rx and ongoing coverage is secured. I authorize pharmacy to dispense VUMER are needed for (A) and (B) about the programment of the Department of th | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction Demonstrated provide up to 4 months of Maintenance Rx, as it are Biogen to forward IT directly to the above to expedite enroll dicaid, Medicare, VA NOT eligible for this it of Defense, DHA. And x7 days x7 days | #14 capsules #360 capsules #360 capsules #120 capsules ns. patients only*) of VUMERITY to my peeded) until the paths prescription to ove-named patient. ment. p. DoD, TRICARE*, an program. TRICARE* all rights reserved. | 3 refills 11 refills 22 refills 23 refills 24 refills 25 refills 26 refills 27 refills 28 refills 28 refills 29 refills 20 refills 20 refills 20 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 27 refills 27 refills 28 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 26 refills 26 refills 26 refills 26 refills 26 refills 27 refills 27 refills 27 refills 28 refills 28 refills 29 refills 20 refills 21 refills 21 refills 22 refills 23 refills 24 refills 25 refills 26 refills 2 | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name City Phone Email Clinical/Hospital affiliat | pies: | Dates: Last name State Fax Tax ID # Office contact | modifying therapy No Known Drug Allergies (NKDA) |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for compartment of the Department | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction Dommercially insured p vide up to 4 months of Maintenance Rx, as in the Biogen to forward ITY directly to the abve to expedite enroll dicaid, Medicare, VA NOT eligible for this t of Defense, DHA. A x7 days x7 days x7 days x14 days | #14 capsules #360 capsules #360 capsules #120 capsules for VUMERITY to my pereded) until the pathis prescription to over-named patient. The program. TRICARE* Il rights reserved. #14 capsules #28 capsules #56 capsules | 3 refills 11 refills 23 refills 24 refills 25 refills 26 refills 27 refills 28 registered 29 refills 30 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name City Phone Email Clinical/Hospital affiliat NPI # | pies: pies: cion ssity and furnish chosen by the a | Dates: Last name State Fax Tax ID # Office contact Prescriber state | modifying therapy modifying therapy No Known Drug Allergies (NKDA) Zip Zip Taip Taip Taip |
| □ Samples have been received □ Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for co □ Yes, I authorize Biogen to prov (one Titration Rx and ongoing coverage is secured. I authorize pharmacy to dispense VUMER are needed for (A) and (B) abo *Patients insured through Met governmental insurance are trademark of the Departmen QuickStart Rx for VUMERITY: Titration Rx 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID Maintenance Rx 462 mg (231 mg x 2) PO BID Prescriber Authorization† I authorize Biogen as my designate above-named patient and (2) forwafor prescribing VUMERITY therapy | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction Dommercially insured p vide up to 4 months of Maintenance Rx, as in the Biogen to forward ITY directly to the abve to expedite enroll dicaid, Medicare, VA NOT eligible for this t of Defense, DHA. A x7 days x7 days x7 days x14 days | #14 capsules #360 capsules #360 capsules #120 capsules for VUMERITY to my pereded) until the pathis prescription to over-named patient. The program. TRICARE* Il rights reserved. #14 capsules #28 capsules #56 capsules | 3 refills 11 refills 23 refills 24 refills 25 refills 26 refills 27 refills 28 registered 29 refills 30 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name City Phone Email Clinical/Hospital affiliat NPI # | pies: pies: cion ssity and furnish chosen by the a | Dates: Last name State Fax Tax ID # Office contact Prescriber state | modifying therapy No Known Drug Allergies (NKDA) Zip Taip Taip Taip Taip |
| □ Samples have been received Prescription for VUMERITY □ Titration Rx for VUMERITY: 231 mg x 1 PO BID 462 mg (231 mg x 2) PO BID No refills Maintenance Rx for VUMERITY: □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID □ 462 mg (231 mg x 2) PO BID See front cover for Healthcare P QuickStart Program (Optional, at no cost to patient for compartment of the Department | THE FOLLOWIN by patient (231 mg) x7 days x23 days x90 days x30 days Provider Instruction mercially insured p vide up to 4 months of Maintenance Rx, as re Biogen to forward ITY directly to the ab ve to expedite enroll dicaid, Medicare, VA NOT eligible for this t of Defense, DHA. A x7 days x7 days x14 days ed agent and on behard the above prescription of the according to th | #14 capsules #360 capsules #360 capsules #120 capsules for VUMERITY to my pereded) until the pathis prescription to over-named patient. The program. TRICARE* Il rights reserved. #14 capsules #28 capsules #56 capsules | 3 refills 11 refills 23 refills 24 refills 25 refills 26 refills 27 refills 28 registered 29 refills 30 refills | ★ Statement of Medi ICD-10: G35 Primary diagnosis Current and Prior Thera Allergies: Prescriber Informa First name City Phone Email Clinical/Hospital affiliat NPI # | pies: tion ssity and furnish chosen by the a nent accordingly | Dates: Last name State Fax Tax ID # Office contact Prescriber state and any information on this overnamed patient. If the contact of t | modifying therapy No Known Drug Allergies (NKDA) Zip Taip Taip Taip Taip |

